Romosozumab in postmenopausal women with low bone mineral density.
about
Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotypeBone repair with skeletal stem cells: rationale, progress to date and clinical applicationSclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and ChallengesSclerostin Inhibition in the Management of OsteoporosisFrom disease to treatment: from rare skeletal disorders to treatments for osteoporosisNew insights into treatment of osteoporosis in postmenopausal womenRecent developments in osteogenesis imperfectaEmerging Therapies for OsteoporosisMale Osteoporosis in the ElderlyRole of bone-anabolic agents in the treatment of breast cancer bone metastasesOsteochemonecrosis: an overviewAnorexia nervosa and bone metabolismFracture healing: mechanisms and interventionsModulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal OsteoporosisOptimal management of bone mineral disorders in chronic kidney disease and end stage renal diseaseThe Bone Marrow-Derived Stromal Cells: Commitment and Regulation of AdipogenesisA randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral densityAntibodies to watch in 2015Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.Novel advances in the treatment of osteoporosis.Efficacy of Osteoporosis Therapies in Diabetic Patients.Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR CohortInhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations.Profile of romosozumab and its potential in the management of osteoporosis.Parathyroid hormone: anabolic and catabolic actions on the skeletonWnt signaling and osteoporosis.Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myelomaThe best of both worlds - managing the cancer, saving the bone.Osteocyte-Secreted Wnt Signaling Inhibitor Sclerostin Contributes to Beige Adipogenesis in Peripheral Fat Depots.Osteoclasts: more than 'bone eaters'.Novel therapeutic targets in myeloma bone disease.Aneuploidy and skeletal health.Inhibitors of sclerostin: emerging concepts.Osteoblasts as leukemia-initiating cells.Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levelsRomosozumab for the treatment of osteoporosis.Wnts produced by Osterix-expressing osteolineage cells regulate their proliferation and differentiation.
P2860
Q21284514-AD4BCD4D-012A-4D46-AD29-0E4540419239Q26744340-A2320758-45E0-49FF-A444-F2962EB1AD22Q26744599-82309B36-29C0-410B-95FF-39B087232341Q26750713-26A86BD5-CF68-4B2C-979B-4BC227CCD81DQ26764854-6FBA69B4-178D-4DA0-B01B-3DB9AA49D940Q26777910-3F46EBD8-8968-49BB-AD6C-CA339BC4A39EQ26781674-EC57E363-A254-484F-88D7-30FA698E4DDBQ26782109-92BD06C2-4737-4005-A8B9-E14D630F8B97Q26784352-40F5479A-A9FB-4BB2-99C1-CFBF34F4EF7BQ26822732-645AF3F5-C5E0-41C8-A817-7B5CD83D01E9Q26827072-8625859E-DE87-40BA-AFF3-3C53CFC959B7Q26829507-65B69814-8D15-4A9B-A7F9-6D1DB3383216Q26851958-5266ACA8-1084-42A5-8299-BBDEA3ED00FFQ27022580-A8296788-32DE-4853-9E98-6E2AD2B4CCE1Q28072340-C07CA955-89FC-4A11-8DCA-D127C597B404Q28078585-02793DF0-9CC7-49AF-A82E-D4BB7E6307F8Q28247445-EC151702-F308-4770-B5DE-4E52383E78DEQ28253501-50DC9DA3-11B2-4657-83BA-0E5270430ADDQ30234751-A66B79DD-6EBB-4565-9F17-01ECDF2D8D32Q30248319-E274B4A1-AB9F-4C05-955B-8A0538FE7A61Q30248776-0F3BAF4D-5CAD-4A5C-AA8B-E9908C6ABDD8Q30713102-3BCDF501-CB7D-43D3-BFA4-CB77380B9437Q31038073-859F7C67-C0A9-4316-95F9-8524EE8BE6A0Q33554916-20BF36D1-F45E-4F60-B784-8583F03D250CQ33596475-9BBAE311-0FC2-4568-AAB9-94F3D69D12FFQ33609126-0CA7C1DD-E73D-4452-939E-7B4BF8D02AE8Q33784662-DC8AFBCF-9EA4-4AF8-A5FA-014CFDEA97DAQ33812106-BF597ED1-FB3B-478C-BADE-3AE28EF02F21Q33835734-F588E956-F639-4A6B-887B-6A98FD71A7EEQ33856318-3EEA7369-737A-4A94-B305-659AAD35416AQ33920055-194BD238-23A0-48F2-8DE2-39C12539B3E2Q33925973-0C1DC909-0419-4001-B9FE-F6BA8B264858Q33993757-E04A8CC4-11CE-46D7-9081-7A03F8D0AB78Q34025065-95EC8A7F-96D0-46B3-9A52-A65D4D60B102Q34059928-89C4C5B1-6E8C-4EE7-A0FA-DF5E4921DF69Q34069470-C8D903E3-03E4-4B7D-AF2A-A87AA922A7FFQ34171839-5E15B3E0-E605-4F37-AF43-E3A4EDCD38D1Q34661015-B8A99B11-975E-4844-AF52-23EFA7D7F50DQ34680463-72DDE465-73BD-40C9-80D8-5A687DDCCF59Q34709060-AC027365-ADF2-44D7-B9F6-F882AC277CE5
P2860
Romosozumab in postmenopausal women with low bone mineral density.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Romosozumab in postmenopausal women with low bone mineral density.
@en
Romosozumab in postmenopausal women with low bone mineral density.
@nl
type
label
Romosozumab in postmenopausal women with low bone mineral density.
@en
Romosozumab in postmenopausal women with low bone mineral density.
@nl
prefLabel
Romosozumab in postmenopausal women with low bone mineral density.
@en
Romosozumab in postmenopausal women with low bone mineral density.
@nl
P2093
P50
P356
P1476
Romosozumab in postmenopausal women with low bone mineral density
@en
P2093
Andreas Grauer
Bente L Langdahl
Cesar Libanati
Henry G Bone
Jean-Yves Reginster
Jose R Zanchetta
Judy Maddox
Leonid Katz
Michael A Bolognese
Scott M Wasserman
P304
P356
10.1056/NEJMOA1305224
P407
P577
2014-01-01T00:00:00Z